Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism
Identifieur interne : 001086 ( PascalFrancis/Corpus ); précédent : 001085; suivant : 001087Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism
Auteurs : John G. Nutt ; Steven A. Gunzler ; Trish Kirchhoff ; Penelope Hogarth ; Jerry L. Weaver ; Michael Krams ; Brenda Jamerson ; Frank S. Menniti ; Jaren W. LandenSource :
- Movement disorders [ 0885-3185 ] ; 2008.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Glutamate antagonists decrease dyskinesia and augment the antiparkinsonian effects of levodopa in animal models of Parkinson's disease (PD). In a randomized, double-blind, placebo-controlled clinical trial, we investigated the acute effects of placebo and two doses of a NR2B subunit selective NMDA glutamate antagonist, CP-101,606, on the response to 2-hour levodopa infusions in 12 PD subjects with motor fluctuations and dyskinesia. Both doses of CP-101,606 reduced the maximum severity of levodopa-induced dyskinesia ∼30% but neither dose improved Parkinsonism. CP-101,606 was associated with a dose-related dissociation and amnesia. These results support the hypothesis that glutamate antagonists may be useful antidyskinetic agents. However, future studies will have to determine if the benefits of dyskinesia suppression can be achieved without adverse cognitive effects.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 08-0522202 INIST |
---|---|
ET : | Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism |
AU : | NUTT (John G.); GUNZLER (Steven A.); KIRCHHOFF (Trish); HOGARTH (Penelope); WEAVER (Jerry L.); KRAMS (Michael); JAMERSON (Brenda); MENNITI (Frank S.); LANDEN (Jaren W.) |
AF : | Department of Neurology, Oregon Health and Science University/Portland, Oregon/Etats-Unis (1 aut., 2 aut., 3 aut., 4 aut.); Pfizer Global Research and Development/Groton, Connecticut/Etats-Unis (5 aut., 6 aut., 8 aut., 9 aut.); VA Medical Center Geriatric Research, Education and Clinical Center and Department of Clinical Research, Campbell University School of Pharmacy/Morrisville, NC/Etats-Unis (7 aut.) |
DT : | Publication en série; Niveau analytique |
SO : | Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2008; Vol. 23; No. 13; Pp. 1860-1866; Bibl. 32 ref. |
LA : | Anglais |
EA : | Glutamate antagonists decrease dyskinesia and augment the antiparkinsonian effects of levodopa in animal models of Parkinson's disease (PD). In a randomized, double-blind, placebo-controlled clinical trial, we investigated the acute effects of placebo and two doses of a NR2B subunit selective NMDA glutamate antagonist, CP-101,606, on the response to 2-hour levodopa infusions in 12 PD subjects with motor fluctuations and dyskinesia. Both doses of CP-101,606 reduced the maximum severity of levodopa-induced dyskinesia ∼30% but neither dose improved Parkinsonism. CP-101,606 was associated with a dose-related dissociation and amnesia. These results support the hypothesis that glutamate antagonists may be useful antidyskinetic agents. However, future studies will have to determine if the benefits of dyskinesia suppression can be achieved without adverse cognitive effects. |
CC : | 002B17; 002B02U01 |
FD : | Dyskinésie; Parkinsonisme; Maladie de Parkinson; Amnésie; Pathologie du système nerveux; NMDA; Glutamate; Lévodopa; Sousunité NR2B |
FG : | Aminoacide excitateur; Neurotransmetteur; Syndrome extrapyramidal; Mouvement involontaire; Trouble neurologique; Pathologie de l'encéphale; Maladie dégénérative; Pathologie du système nerveux central; Trouble de la mémoire; Trouble cognitif |
ED : | Dyskinesia; Parkinsonism; Parkinson disease; Amnesia; Nervous system diseases; NMDA; Glutamate; Levodopa |
EG : | Excitatory aminoacid; Neurotransmitter; Extrapyramidal syndrome; Involuntary movement; Neurological disorder; Cerebral disorder; Degenerative disease; Central nervous system disease; Memory disorder; Cognitive disorder |
SD : | Disquinesia; Parkinson síndrome; Parkinson enfermedad; Amnesia; Sistema nervioso patología; NMDA; Glutamato; Levodopa |
LO : | INIST-20953.354000184468160100 |
ID : | 08-0522202 |
Links to Exploration step
Pascal:08-0522202Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism</title>
<author><name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G." last="Nutt">John G. Nutt</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health and Science University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gunzler, Steven A" sort="Gunzler, Steven A" uniqKey="Gunzler S" first="Steven A." last="Gunzler">Steven A. Gunzler</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health and Science University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kirchhoff, Trish" sort="Kirchhoff, Trish" uniqKey="Kirchhoff T" first="Trish" last="Kirchhoff">Trish Kirchhoff</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health and Science University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hogarth, Penelope" sort="Hogarth, Penelope" uniqKey="Hogarth P" first="Penelope" last="Hogarth">Penelope Hogarth</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health and Science University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Weaver, Jerry L" sort="Weaver, Jerry L" uniqKey="Weaver J" first="Jerry L." last="Weaver">Jerry L. Weaver</name>
<affiliation><inist:fA14 i1="02"><s1>Pfizer Global Research and Development</s1>
<s2>Groton, Connecticut</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Krams, Michael" sort="Krams, Michael" uniqKey="Krams M" first="Michael" last="Krams">Michael Krams</name>
<affiliation><inist:fA14 i1="02"><s1>Pfizer Global Research and Development</s1>
<s2>Groton, Connecticut</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jamerson, Brenda" sort="Jamerson, Brenda" uniqKey="Jamerson B" first="Brenda" last="Jamerson">Brenda Jamerson</name>
<affiliation><inist:fA14 i1="03"><s1>VA Medical Center Geriatric Research, Education and Clinical Center and Department of Clinical Research, Campbell University School of Pharmacy</s1>
<s2>Morrisville, NC</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Menniti, Frank S" sort="Menniti, Frank S" uniqKey="Menniti F" first="Frank S." last="Menniti">Frank S. Menniti</name>
<affiliation><inist:fA14 i1="02"><s1>Pfizer Global Research and Development</s1>
<s2>Groton, Connecticut</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Landen, Jaren W" sort="Landen, Jaren W" uniqKey="Landen J" first="Jaren W." last="Landen">Jaren W. Landen</name>
<affiliation><inist:fA14 i1="02"><s1>Pfizer Global Research and Development</s1>
<s2>Groton, Connecticut</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0522202</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0522202 INIST</idno>
<idno type="RBID">Pascal:08-0522202</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001086</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism</title>
<author><name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G." last="Nutt">John G. Nutt</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health and Science University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gunzler, Steven A" sort="Gunzler, Steven A" uniqKey="Gunzler S" first="Steven A." last="Gunzler">Steven A. Gunzler</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health and Science University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kirchhoff, Trish" sort="Kirchhoff, Trish" uniqKey="Kirchhoff T" first="Trish" last="Kirchhoff">Trish Kirchhoff</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health and Science University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hogarth, Penelope" sort="Hogarth, Penelope" uniqKey="Hogarth P" first="Penelope" last="Hogarth">Penelope Hogarth</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Oregon Health and Science University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Weaver, Jerry L" sort="Weaver, Jerry L" uniqKey="Weaver J" first="Jerry L." last="Weaver">Jerry L. Weaver</name>
<affiliation><inist:fA14 i1="02"><s1>Pfizer Global Research and Development</s1>
<s2>Groton, Connecticut</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Krams, Michael" sort="Krams, Michael" uniqKey="Krams M" first="Michael" last="Krams">Michael Krams</name>
<affiliation><inist:fA14 i1="02"><s1>Pfizer Global Research and Development</s1>
<s2>Groton, Connecticut</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Jamerson, Brenda" sort="Jamerson, Brenda" uniqKey="Jamerson B" first="Brenda" last="Jamerson">Brenda Jamerson</name>
<affiliation><inist:fA14 i1="03"><s1>VA Medical Center Geriatric Research, Education and Clinical Center and Department of Clinical Research, Campbell University School of Pharmacy</s1>
<s2>Morrisville, NC</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Menniti, Frank S" sort="Menniti, Frank S" uniqKey="Menniti F" first="Frank S." last="Menniti">Frank S. Menniti</name>
<affiliation><inist:fA14 i1="02"><s1>Pfizer Global Research and Development</s1>
<s2>Groton, Connecticut</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Landen, Jaren W" sort="Landen, Jaren W" uniqKey="Landen J" first="Jaren W." last="Landen">Jaren W. Landen</name>
<affiliation><inist:fA14 i1="02"><s1>Pfizer Global Research and Development</s1>
<s2>Groton, Connecticut</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amnesia</term>
<term>Dyskinesia</term>
<term>Glutamate</term>
<term>Levodopa</term>
<term>NMDA</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Parkinsonism</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dyskinésie</term>
<term>Parkinsonisme</term>
<term>Maladie de Parkinson</term>
<term>Amnésie</term>
<term>Pathologie du système nerveux</term>
<term>NMDA</term>
<term>Glutamate</term>
<term>Lévodopa</term>
<term>Sousunité NR2B</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Glutamate antagonists decrease dyskinesia and augment the antiparkinsonian effects of levodopa in animal models of Parkinson's disease (PD). In a randomized, double-blind, placebo-controlled clinical trial, we investigated the acute effects of placebo and two doses of a NR2B subunit selective NMDA glutamate antagonist, CP-101,606, on the response to 2-hour levodopa infusions in 12 PD subjects with motor fluctuations and dyskinesia. Both doses of CP-101,606 reduced the maximum severity of levodopa-induced dyskinesia ∼30% but neither dose improved Parkinsonism. CP-101,606 was associated with a dose-related dissociation and amnesia. These results support the hypothesis that glutamate antagonists may be useful antidyskinetic agents. However, future studies will have to determine if the benefits of dyskinesia suppression can be achieved without adverse cognitive effects.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>23</s2>
</fA05>
<fA06><s2>13</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>NUTT (John G.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>GUNZLER (Steven A.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KIRCHHOFF (Trish)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>HOGARTH (Penelope)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>WEAVER (Jerry L.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>KRAMS (Michael)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>JAMERSON (Brenda)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>MENNITI (Frank S.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>LANDEN (Jaren W.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, Oregon Health and Science University</s1>
<s2>Portland, Oregon</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Pfizer Global Research and Development</s1>
<s2>Groton, Connecticut</s2>
<s3>USA</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>VA Medical Center Geriatric Research, Education and Clinical Center and Department of Clinical Research, Campbell University School of Pharmacy</s1>
<s2>Morrisville, NC</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>1860-1866</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000184468160100</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>32 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0522202</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Glutamate antagonists decrease dyskinesia and augment the antiparkinsonian effects of levodopa in animal models of Parkinson's disease (PD). In a randomized, double-blind, placebo-controlled clinical trial, we investigated the acute effects of placebo and two doses of a NR2B subunit selective NMDA glutamate antagonist, CP-101,606, on the response to 2-hour levodopa infusions in 12 PD subjects with motor fluctuations and dyskinesia. Both doses of CP-101,606 reduced the maximum severity of levodopa-induced dyskinesia ∼30% but neither dose improved Parkinsonism. CP-101,606 was associated with a dose-related dissociation and amnesia. These results support the hypothesis that glutamate antagonists may be useful antidyskinetic agents. However, future studies will have to determine if the benefits of dyskinesia suppression can be achieved without adverse cognitive effects.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B02U01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinsonisme</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinsonism</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson síndrome</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Amnésie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Amnesia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Amnesia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Pathologie du système nerveux</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>NMDA</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>NMDA</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>NMDA</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Glutamate</s0>
<s2>NK</s2>
<s2>FX</s2>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Glutamate</s0>
<s2>NK</s2>
<s2>FX</s2>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Glutamato</s0>
<s2>NK</s2>
<s2>FX</s2>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Sousunité NR2B</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Aminoacide excitateur</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Excitatory aminoacid</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aminoácido excitador</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>43</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>44</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>44</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Pathologie du système nerveux central</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>45</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>45</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Trouble de la mémoire</s0>
<s5>46</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Memory disorder</s0>
<s5>46</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Trastorno memoria</s0>
<s5>46</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Trouble cognitif</s0>
<s5>47</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Cognitive disorder</s0>
<s5>47</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Trastorno cognitivo</s0>
<s5>47</s5>
</fC07>
<fN21><s1>343</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 08-0522202 INIST</NO>
<ET>Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism</ET>
<AU>NUTT (John G.); GUNZLER (Steven A.); KIRCHHOFF (Trish); HOGARTH (Penelope); WEAVER (Jerry L.); KRAMS (Michael); JAMERSON (Brenda); MENNITI (Frank S.); LANDEN (Jaren W.)</AU>
<AF>Department of Neurology, Oregon Health and Science University/Portland, Oregon/Etats-Unis (1 aut., 2 aut., 3 aut., 4 aut.); Pfizer Global Research and Development/Groton, Connecticut/Etats-Unis (5 aut., 6 aut., 8 aut., 9 aut.); VA Medical Center Geriatric Research, Education and Clinical Center and Department of Clinical Research, Campbell University School of Pharmacy/Morrisville, NC/Etats-Unis (7 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2008; Vol. 23; No. 13; Pp. 1860-1866; Bibl. 32 ref.</SO>
<LA>Anglais</LA>
<EA>Glutamate antagonists decrease dyskinesia and augment the antiparkinsonian effects of levodopa in animal models of Parkinson's disease (PD). In a randomized, double-blind, placebo-controlled clinical trial, we investigated the acute effects of placebo and two doses of a NR2B subunit selective NMDA glutamate antagonist, CP-101,606, on the response to 2-hour levodopa infusions in 12 PD subjects with motor fluctuations and dyskinesia. Both doses of CP-101,606 reduced the maximum severity of levodopa-induced dyskinesia ∼30% but neither dose improved Parkinsonism. CP-101,606 was associated with a dose-related dissociation and amnesia. These results support the hypothesis that glutamate antagonists may be useful antidyskinetic agents. However, future studies will have to determine if the benefits of dyskinesia suppression can be achieved without adverse cognitive effects.</EA>
<CC>002B17; 002B02U01</CC>
<FD>Dyskinésie; Parkinsonisme; Maladie de Parkinson; Amnésie; Pathologie du système nerveux; NMDA; Glutamate; Lévodopa; Sousunité NR2B</FD>
<FG>Aminoacide excitateur; Neurotransmetteur; Syndrome extrapyramidal; Mouvement involontaire; Trouble neurologique; Pathologie de l'encéphale; Maladie dégénérative; Pathologie du système nerveux central; Trouble de la mémoire; Trouble cognitif</FG>
<ED>Dyskinesia; Parkinsonism; Parkinson disease; Amnesia; Nervous system diseases; NMDA; Glutamate; Levodopa</ED>
<EG>Excitatory aminoacid; Neurotransmitter; Extrapyramidal syndrome; Involuntary movement; Neurological disorder; Cerebral disorder; Degenerative disease; Central nervous system disease; Memory disorder; Cognitive disorder</EG>
<SD>Disquinesia; Parkinson síndrome; Parkinson enfermedad; Amnesia; Sistema nervioso patología; NMDA; Glutamato; Levodopa</SD>
<LO>INIST-20953.354000184468160100</LO>
<ID>08-0522202</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001086 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001086 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:08-0522202 |texte= Effects of a NR2B Selective NMDA Glutamate Antagonist, CP-101,606, on Dyskinesia and Parkinsonism }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |